The chemical structure of a bioidentical hormone, like other natural substances, can not be patented, so there is very little financial incentive for a drug company to spend all that money on clinical studies when profits can not be assured. (bioidenticalhormones101.com)
But if emissions are significantly lower than the cap, there would be less demand for allowances, driving down their price and giving power plants little financial incentive to invest in cleaner and more efficient technologies... (climate-skeptic.com)
The FDA does provide recommendations for drugmakers to do that voluntarily, but the companies have little financial incentive to do so. (cnbc.com)